Hemostemix Inc. (HMTXF)
USD 0.07
(4.99%)
USD 0.07
(4.99%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 4.16 Million CAD | 4.41% |
| 2022 | 3.99 Million CAD | 216.08% |
| 2021 | 1.26 Million CAD | 1621.82% |
| 2020 | -82.95 Thousand CAD | -104.07% |
| 2019 | 2.04 Million CAD | 238.69% |
| 2018 | -1.47 Million CAD | 62.84% |
| 2017 | -3.95 Million CAD | -391.87% |
| 2016 | 1.35 Million CAD | 367.74% |
| 2015 | -506.58 Thousand CAD | 84.67% |
| 2014 | -3.3 Million CAD | -841.2% |
| 2013 | -351.19 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 4.51 Million CAD | 1.84% |
| 2024 Q1 | 4.43 Million CAD | 6.37% |
| 2023 FY | 4.16 Million CAD | 4.41% |
| 2023 Q1 | 3.74 Million CAD | -6.02% |
| 2023 Q4 | 4.16 Million CAD | 6.46% |
| 2023 Q3 | 3.91 Million CAD | -2.92% |
| 2023 Q2 | 4.03 Million CAD | 7.49% |
| 2022 Q3 | 1.62 Million CAD | -14.05% |
| 2022 FY | 3.99 Million CAD | 216.08% |
| 2022 Q1 | 475.74 Thousand CAD | -62.31% |
| 2022 Q2 | 1.89 Million CAD | 297.63% |
| 2022 Q4 | 3.99 Million CAD | 145.39% |
| 2021 Q1 | -537.87 Thousand CAD | -548.43% |
| 2021 FY | 1.26 Million CAD | 1621.82% |
| 2021 Q2 | 588.3 Thousand CAD | 209.37% |
| 2021 Q4 | 1.26 Million CAD | 58.05% |
| 2021 Q3 | 798.7 Thousand CAD | 35.76% |
| 2020 Q1 | -171.76 Thousand CAD | -108.42% |
| 2020 Q2 | -409.85 Thousand CAD | -138.62% |
| 2020 Q3 | -70.17 Thousand CAD | 82.88% |
| 2020 Q4 | -82.95 Thousand CAD | -18.21% |
| 2020 FY | -82.95 Thousand CAD | -104.07% |
| 2019 Q3 | 1.74 Million CAD | 297.83% |
| 2019 Q2 | 438.48 Thousand CAD | 169.76% |
| 2019 FY | 2.04 Million CAD | 238.69% |
| 2019 Q1 | -628.51 Thousand CAD | 57.27% |
| 2019 Q4 | 2.04 Million CAD | 16.96% |
| 2018 Q2 | -3.86 Million CAD | 21.76% |
| 2018 FY | -1.47 Million CAD | 62.84% |
| 2018 Q1 | -4.93 Million CAD | -24.72% |
| 2018 Q3 | -2.6 Million CAD | 32.67% |
| 2018 Q4 | -1.47 Million CAD | 43.45% |
| 2017 Q4 | -3.95 Million CAD | 28.75% |
| 2017 Q2 | 1.23 Million CAD | 38.48% |
| 2017 Q3 | -5.55 Million CAD | -549.42% |
| 2017 Q1 | 892.73 Thousand CAD | -34.18% |
| 2017 FY | -3.95 Million CAD | -391.87% |
| 2016 Q3 | 1.2 Million CAD | 262.79% |
| 2016 FY | 1.35 Million CAD | 367.74% |
| 2016 Q4 | 1.35 Million CAD | 12.36% |
| 2016 Q2 | 332.73 Thousand CAD | 105.0% |
| 2016 Q1 | 162.3 Thousand CAD | 132.04% |
| 2015 Q3 | -707.75 Thousand CAD | 59.49% |
| 2015 Q1 | -2.59 Million CAD | 21.47% |
| 2015 Q2 | -1.74 Million CAD | 32.69% |
| 2015 FY | -506.58 Thousand CAD | 84.67% |
| 2015 Q4 | -506.58 Thousand CAD | 28.42% |
| 2014 Q3 | -105.19 Thousand CAD | 38.8% |
| 2014 FY | -3.3 Million CAD | -841.2% |
| 2014 Q1 | -182.38 Thousand CAD | 10.19% |
| 2014 Q4 | -3.3 Million CAD | -3042.34% |
| 2014 Q2 | -171.87 Thousand CAD | 5.76% |
| 2013 Q4 | -203.08 Thousand CAD | -3.85% |
| 2013 Q3 | -195.56 Thousand CAD | 19.77% |
| 2013 Q1 | -291.45 Thousand CAD | -303.68% |
| 2013 FY | -351.19 Thousand CAD | 0.0% |
| 2013 Q2 | -243.74 Thousand CAD | 16.37% |
| 2012 Q3 | -77.55 Thousand CAD | 0.0% |
| 2012 Q4 | -72.19 Thousand CAD | 6.9% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 20.27 Million USD | 79.453% |
| Skye Bioscience, Inc. | -5.72 Million USD | 172.816% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 166.081% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 1768.972% |
| Qrons Inc. | 351.42 Thousand USD | -1085.477% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 6.841% |
| CSL Limited | 10.52 Billion USD | 99.96% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 90.265% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 26.243% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -555.904% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 90.408% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 20513.995% |
| Rebus Holdings, Inc. | 305 Thousand USD | -1265.93% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 318121.985% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -569.397% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -20869.89% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 73.57% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -1.167% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -936.73% |
| SQZ Biotechnologies Company | -36.23 Million USD | 111.496% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -85.801% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -349.326% |
| Mesoblast Limited | 55.85 Million USD | 92.542% |
| Marizyme, Inc. | 18.56 Million USD | 77.564% |
| Genus plc | 190.6 Million USD | 97.814% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -86.333% |
| Pharming Group N.V. | 109.8 Million USD | 96.206% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -384.293% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -243.202% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -512.66% |
| ContraFect Corporation | -6.02 Million USD | 169.135% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -2994.265% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -260.566% |
| IMV Inc. | 7.67 Million USD | 45.687% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 24.279% |
| MultiCell Technologies, Inc. | 90.04 USD | -4626830.253% |
| ONE Bio Corp. | 9.04 Million USD | 53.915% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 667.604% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 67.819% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -204.545% |
| Q BioMed Inc. | 4.06 Million USD | -2.613% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 86.365% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -313.419% |
| Biomind Labs Inc. | 711.4 Thousand USD | -485.617% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 93.119% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -108.368% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 67.469% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1058.18% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -2879.949% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -89.197% |
| GB Sciences, Inc. | 1.74 Million USD | -138.428% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 2366.79% |
| HST Global, Inc. | 96.79 Thousand USD | -4204.121% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -1920.245% |
| Halberd Corporation | 144.72 Thousand USD | -2778.703% |
| Enzolytics Inc. | 981.65 Thousand USD | -324.394% |
| Agentix Corp. | 37.63 Thousand USD | -10970.894% |
| Resverlogix Corp. | 6.45 Million USD | 35.42% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 718.951% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.205% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 108.862% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 41.082% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -53.809% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 147.128% |
| AVAX Technologies, Inc. | -5.9 Million USD | 170.573% |
| Zenith Capital Corp. | 10.06 Thousand USD | -41295.946% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.393% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -1978.554% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -74.603% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -2432.438% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 22843.138% |
| Kadimastem Ltd | -253.1 Thousand USD | 1746.011% |
| Helix BioMedix, Inc. | -2.57 Million USD | 262.103% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -1970.065% |
| LadRx Corporation | -2.03 Million USD | 304.574% |
| Cell Source, Inc. | 9.23 Million USD | 54.873% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -555.904% |
| NovAccess Global Inc. | 2.17 Million USD | -91.24% |
| Affymax, Inc. | -5.59 Million USD | 174.434% |
| Itoco Inc. | 228.3 Thousand USD | -1724.791% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -2963.548% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 15.955% |
| Mobile Lads Corp. | 484.23 Thousand USD | -760.35% |
| CytoDyn Inc. | 20.26 Million USD | 79.439% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 644008.501% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 45049.667% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 45.937% |
| SYBLEU INC | 473.71 Thousand USD | -779.452% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 6.528% |
| International Stem Cell Corporation | 2.59 Million USD | -60.853% |
| Bioxytran, Inc. | 1.89 Million USD | -119.393% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -6575.032% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -91.026% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -21.319% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 51.291% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -439.225% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 433.287% |
| Neutra Corp. | 52.18 Thousand USD | -7883.0% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 267.38% |
| PureTech Health plc | -167.19 Million USD | 102.492% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 1801.083% |
| IXICO plc | -4.44 Million USD | 193.734% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 68.484% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 92.405% |
| CSL Limited | 10.52 Billion USD | 99.96% |
| Cellectis S.A. | -43.81 Million USD | 109.508% |